Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label Study of ABSK061 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumors

NCT05244551 is registered in ClinicalTrials.gov with Abbisko Therapeutics Co, Ltd as lead sponsor.

NCT NCT05244551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05244551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label Study of ABSK061 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumors
Lead sponsor
Abbisko Therapeutics Co, Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
June 30, 2022
Completion date
April 30, 2025
Enrollment
85 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor